Dellinger, Ryan,Rhonemus, Troy,Morris, Mark,Erickson, Aron,Casser, Hadi,Migaud, Marie E.
申请号：
AU2017254657
公开号：
AU2017254657A1
申请日:
2017.04.20
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
Compositions are provided including nicotinic acid riboside ("NAR"), and derivatives thereof including l -(2',3 ',5'-triacetyl-beta-D-ribofuranosyl)-nicotinic acid ("NAR triacetate" or "NARTA")； or derivatives of a reduced form of nicotinic acid riboside ("NARH"), including 1 - (2',3',5 '-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid ("NARH triacetate" or "NARJT-TA")； or derivatives of nicotinamide riboside ("NR"), including 1 -(2',3',5'-triacetyl- beta-D-ribofuranosyl)-nicotinamide ("NR triacetate" or "NRTA")； derivatives of a reduced form of nicotinamide riboside ("NRH"), including 1-(2',3 ',5'-triacetyl-beta-D-ribofuranosyl)- 1,4- dihydronicotinamide ("NRH triacetate" or "NRH-TA")； or salts or prodrugs thereof, for use in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. Methods of using the compounds above to promote the increase of intracellular levels of nicotinamide adenine dinuc!eotide ("NAD+") or NADH in cells and tissues for improving cell and tissue survival or overall cell and tissue health are provided.
